Arindom Pal

Arindom Pal

Johns Hopkins University

H-index: 9

North America-United States

About Arindom Pal

Arindom Pal, With an exceptional h-index of 9 and a recent h-index of 9 (since 2020), a distinguished researcher at Johns Hopkins University, specializes in the field of Drug Metabolism and Pharmacokinetics.

His recent articles reflect a diverse array of research interests and contributions to the field:

Leveraging Modeling and Simulation to Enhance the Efficiency of Bioequivalence Approaches for Generic Drugs: Highlights from the 2023 Generic Drug Science and Research …

Investigating inhibitors of 1-deoxy-d-xylulose 5-phosphate synthase in a mouse model of UTI

Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model

Neutral sphingomyelinase 2 inhibitors based on the pyrazolo [1, 5-a] pyrimidin-3-amine scaffold

ASENT 2023 Annual Meeting Abstracts

nSMase2 inhibition reduces tau propagation in Alzheimer’s Disease mouse models

Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug

Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand

Arindom Pal Information

University

Position

___

Citations(all)

411

Citations(since 2020)

300

Cited By

176

hIndex(all)

9

hIndex(since 2020)

9

i10Index(all)

9

i10Index(since 2020)

9

Email

University Profile Page

Google Scholar

Arindom Pal Skills & Research Interests

Drug Metabolism and Pharmacokinetics

Top articles of Arindom Pal

Leveraging Modeling and Simulation to Enhance the Efficiency of Bioequivalence Approaches for Generic Drugs: Highlights from the 2023 Generic Drug Science and Research …

The AAPS Journal

2024/4/8

Investigating inhibitors of 1-deoxy-d-xylulose 5-phosphate synthase in a mouse model of UTI

Microbiology Spectrum

2024/2/20

Arindom Pal
Arindom Pal

H-Index: 5

Rana Rais
Rana Rais

H-Index: 20

Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model

Translational Neurodegeneration

2023/12/4

Neutral sphingomyelinase 2 inhibitors based on the pyrazolo [1, 5-a] pyrimidin-3-amine scaffold

European journal of medicinal chemistry

2019/5/15

ASENT 2023 Annual Meeting Abstracts

2023

nSMase2 inhibition reduces tau propagation in Alzheimer’s Disease mouse models

Alzheimer's & Dementia

2022/12

Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug

Science Advances

2022/11/16

Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand

Journal of Medicinal Chemistry

2022/11/3

Arindom Pal
Arindom Pal

H-Index: 5

Dendrimer-conjugated nSMase2 inhibitor reduces tau propagation in mice

Pharmaceutics

2022/9/28

D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II

Pharmaceutics

2022/9/23

Discovery of orally bioavailable and brain-penetrable prodrugs of the potent nSmase2 inhibitor DPTIP

Journal of medicinal chemistry

2022/8/5

Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury

Biochemical pharmacology

2021/12/1

Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor

Bioorganic & medicinal chemistry letters

2021/10/15

Glutamine antagonist GA-607 causes a dramatic accumulation of FGAR which can be used to monitor target engagement

Current drug metabolism

2021/8/8

Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases

2021/7/1

BSCD Oral: Biological & Health Sciences

University of Chicago Undergraduate Research Symposium Proceedings

2020/5/28

See List of Professors in Arindom Pal University(Johns Hopkins University)